IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received
IRLAB Therapeutics AB (“IRLAB” or the “Company”) has prepared an information document (the “Information Document”) in connection with the rights issue of ordinary shares of series A which the Board of Directors, conditional upon subsequent approval by an extraordinary general meeting and amendment of the articles of association, resolved on 5 May 2026 (the “Rights Issue”). The extraordinary general meeting on 5 June 2026 approved the Board of Directors’ resolution on the Rights Issue and amendment of the articles of association, which was announced earlier today. The Information Document is available on the Company’s website, www.irlab.se. The Information Document will also be made available on Aqurat Fondkommission AB’s website, www.aqurat.se. IRLAB further announces that the Company has received additional subscription undertakings of a total of approximately SEK 1.8 million, of which the majority were previously subscription intentions, and in aggregate the subscription undertakings received amount to approximately SEK 56.8 million, corresponding to approximately 84 percent of the Rights Issue. Of previously communicated subscription intentions, one subscription intention of approximately SEK 4.9 million remains, corresponding to approximately 7.2 percent of the Rights Issue. In total, the Rights Issue is thus covered to approximately 91 percent through subscription undertakings and subscription intentions.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
Kristina Torfgård, CEO, presents at Redeye Healthcare Day 2026
Kristina Torfgård, CEO, presented at Redeye Healthcare Day on April 14, 2026. Presentation in Swedish.
Read More >